Evidence map›Paper›PMID 35173808›Full record

ArticleTherapeutic advances in neurological disorders2021

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients.

Kimberley Allen-Philbey, Stefania De Trane, Zhifeng Mao, Cesar Álvarez-González, Joela Mathews, Amy MacDougall, Andrea Stennett, Xia Zhou, Ozlem Yildiz, Ashok Adams and 28 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in neurological disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 20 institutions in 4 countries.

Kimberley Allen-PhilbeyNeuroscience, Clinical Board Medicine, The Royal London Hospital, Barts Health NHS Trust, London, UK.ORCID https://orcid.org/0000-0003-1207-8625
Stefania De TraneNeuroscience, Surgery and Trauma, The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.
Zhifeng MaoKingmed College of Laboratory Medicine, Guangzhou Medical University, Guangzhou, China.
Cesar Álvarez-GonzálezNeurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, Basel, Switzerland.
Joela MathewsPharmacy Department, The Royal London Hospital, Barts Health NHS Trust, London, UK.
Amy MacDougallDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
Andrea StennettNeuroscience, Clinical Board Medicine, The Royal London Hospital, Barts Health NHS Trust, London, UK.
Xia ZhouNeuroscience, Clinical Board Medicine, The Royal London Hospital, Barts Health NHS Trust, London, UK.
Ozlem YildizNeuroscience, Clinical Board Medicine, The Royal London Hospital, Barts Health NHS Trust, London, UK.
Ashok AdamsNeuroradiology Department, The Royal London Hospital, Barts Health NHS Trust, London, UK.
Lucia BianchiNeuroscience, Surgery and Trauma, The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.
Camilla BlainSt George's University Hospitals NHS Foundation Trust, London, UK.
Christine ChapmanNeuroscience, Surgery and Trauma, The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.
Karen ChungThe National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.
Cris S ConstantinescuDepartment of Neurology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Catherine DaltonSt George's University Hospitals NHS Foundation Trust, London, UK.
Rachel A FarrellThe National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.
Leonora FisnikuBrighton and Sussex University Hospitals NHS Trust, Brighton, UK; Brighton and Sussex Medical School, Brighton, UK.
Helen FordLeeds Teaching Hospitals NHS Trust, Leeds, UK.
Bruno GranDepartment of Neurology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Jeremy HobartPlymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK.
Zhaleh KhaleeliDepartment of Neuroinflammation, National Hospital for Neurology and Neurosurgery, London, UK.
Miriam MattoscioQueen's Hospital, Barking Havering and Redbridge Hospital NHS Trust, Romford, UK; Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
Sue PavittDental Translational and Clinical Research Unit, School of Dentistry, University of Leeds, Leeds, UK.
Owen PearsonDepartment of Neurology, Swansea Bay University Health Board, Port Talbot, UK.
Luca Peruzzotti-JamettiDepartment of Clinical Neurosciences and National Institute for Health Research (NIHR) Biomedical Research Centre, University of Cambridge, Cambridge, UK.
Antonio ScalfariCentre of Neuroscience, Department of Medicine Charing Cross Hospital, Imperial College London, London, UK.
Basil SharrackDepartment of Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Eli SilberDepartment of Neurology, King's College Hospital, London, UK.
Emma C TallantyreDepartment of Neurology, University Hospital of Wales, Cardiff, UK.
Stewart WebbInstitute of Neuroscience, Department of Neurology, Queen Elizabeth University Hospital, Glasgow, UK.
Benjamin P TurnerNeuroscience, Clinical Board Medicine, The Royal London Hospital, Barts Health NHS Trust, London, UK.
Monica MartaNeuroscience, Clinical Board Medicine, The Royal London Hospital, Barts Health NHS Trust, London, UK.
Sharmilee GnanapavanNeuroscience, Clinical Board Medicine, The Royal London Hospital, Barts Health NHS Trust, London, UK.
Gunnar JuliussonDepartment of Hematology, Skåne University Hospital, Lund, Sweden.
Gavin GiovannoniNeuroscience, Clinical Board Medicine, The Royal London Hospital, Barts Health NHS Trust, London, UK.ORCID https://orcid.org/0000-0001-9995-1700
David BakerNeuroscience, Surgery and Trauma, The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.
Klaus SchmiererNeuroscience, Clinical Board Medicine, The Royal London Hospital, Barts Health NHS Trust, London, UK Neuroscience, Surgery and Trauma, The Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, UK.ORCID https://orcid.org/0000-0002-9293-8893
Queen Mary University of London · GBBarts Health NHS Trust · GBNottingham University Hospitals NHS Trust · GBSt George’s University Hospitals NHS Foundation Trust · GBUniversity College London Hospitals NHS Foundation Trust · GBBarking, Havering And Redbridge University Hospitals NHS Trust · GBBrighton and Sussex Medical School · GBCharing Cross Hospital · GBKingmed Diagnostics · CNKing's College Hospital · GBLeeds Teaching Hospitals NHS Trust · GBLondon School of Hygiene & Tropical Medicine · GBLund University · SENational Hospital for Neurology and Neurosurgery · GBPeninsula College of Medicine and Dentistry · GBQueen Elizabeth University Hospital · GBSheffield Teaching Hospitals NHS Foundation Trust · GBSwansea Bay University Health Board · GBUniversity Hospital of Wales · GBUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo report on safety and effectiveness of subcutaneous cladribine (Litak

methodsLitak

resultsIn all, 208 patients received at least one course of treatment. Age at baseline was 44 (17-72) years and EDSS 0-8.5. Cladribine was generally well tolerated. One myocardial infarction, one breast cancer, and three severe skin reactions occurred without long-term sequelae. Two patients died (one pneumonia, one encephalitis). Lymphopenia grade 3 occurred in 5% and grade 4 in 0.5%. In 94 out of 116 pwMS with baseline and follow-up (BaFU) data after two treatment courses, EDSS remained stable or improved. At 18 months, 64% of patients with relapsing MS and BaFU data (

conclusionsLitak

Indexed as

cladribinedisease-modifying treatmentmultiple sclerosisNEDANEPADtreatment access

Identifiers

PMID35173808
PMCPMC8842147
OpenAlexW3217164253

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.